Bellicum to Participate in Two Upcoming Virtual Investor Conferences

Bellicum Pharmaceuticals (NASDAQ:BLCM) announced its participation in two virtual investor conferences.

Rhea-AI Summary

Bellicum Pharmaceuticals (NASDAQ:BLCM) announced its participation in two virtual investor conferences. The first is the Jefferies Virtual Healthcare Conference, scheduled for June 3, 2020, at 4:00 p.m. EDT, featuring a fireside chat format. The second is the Investor Summit Virtual Summer Summit on June 10, 2020, at 3:20 p.m. EDT, in a presentation format. Live webcasts will be available on Bellicum's website, with archived versions accessible post-event. Bellicum specializes in controllable cellular immunotherapies, aiming to enhance CAR-T and CAR-NK cell therapies.

Argus Session date unavailable

+1.38% session move Open Argus

Details

News Market Reaction – BLCM

The recorded move for BLCM in the trading session of this news was +1.38%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HOUSTON, May 27, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that management will participate in two upcoming virtual investor conferences.

Conference Details:

Jefferies Virtual Healthcare Conference
Date/Time: Wednesday, June 3, 2020 at 4:00 p.m. EDT
Format: Fireside Chat

Investor Summit Virtual Summer Summit
Date/Time: Wednesday, June 10, 2020 at 3:20 p.m. EDT
Format: Presentation

Live webcasts of the fireside chat and presentation may be accessed from the Events & Presentation section of the Bellicum website. An archived version of each webcast will be available for replay immediately following the event.

About Bellicum Pharmaceuticals

Bellicum is a clinical stage biopharmaceutical company striving to deliver cures through controllable cell therapies. The company’s next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce more effective CAR-T and CAR-NK cell therapies. Bellicum’s lead GoCAR-T^® candidate, BPX-601, is designed to be a more efficacious CAR-T cell product capable of overriding key immune inhibitory mechanisms. More information about Bellicum can be found at www.bellicum.com.

Source: Bellicum Pharmaceuticals

Investors:
Robert H. Uhl
Managing Director
Westwicke ICR
858-356-5932
Robert.uhl@westwicke.com

 

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What are the details of Bellicum Pharmaceuticals' participation in the Jefferies Virtual Healthcare Conference?

Bellicum Pharmaceuticals will participate in the Jefferies Virtual Healthcare Conference on June 3, 2020, at 4:00 p.m. EDT in a fireside chat format.

When is the Investor Summit Virtual Summer Summit that Bellicum Pharmaceuticals will attend?

The Investor Summit Virtual Summer Summit is scheduled for June 10, 2020, at 3:20 p.m. EDT.

How can I access the webcasts for Bellicum Pharmaceuticals' investor conferences?

The live webcasts for Bellicum Pharmaceuticals' investor conferences can be accessed via the Events & Presentation section on their website, with archived versions available for replay after the events.

What is Bellicum Pharmaceuticals focused on in their research and development?

Bellicum Pharmaceuticals focuses on developing controllable cellular immunotherapies, particularly enhancing CAR-T and CAR-NK cell therapies through innovative signaling technologies.